Schwartzberg LS - Search Results

1

Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.

Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Goetz MP, et al. Among authors: schwartzberg ls. Ann Oncol. 2023 Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. Ann Oncol. 2023. PMID: 38072514 Free article. Clinical Trial.

2

Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.

Navari R, Binder G, Molasiotis A, Herrstedt J, Roeland EJ, Ruddy KJ, LeBlanc TW, Kloth DD, Klute KA, Papademetriou E, Schmerold L, Schwartzberg L. Navari R, et al. Oncologist. 2023 Mar 17;28(3):208-213. doi: 10.1093/oncolo/oyac240. Oncologist. 2023. PMID: 36527702 Free PMC article.

3

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.

Schwartzberg L, Navari RM, Ruddy KJ, LeBlanc TW, Clark-Snow R, Wickham R, Kloth D, Binder G, Bailey WL, Turini M, Potluri R, Liu X, Papademetriou E, Roeland EJ. Schwartzberg L, et al. Support Care Cancer. 2023 Oct 25;31(12):654. doi: 10.1007/s00520-023-08119-1. Support Care Cancer. 2023. PMID: 37878086 Free PMC article.

4

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.

Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, O'Shaughnessy JA, Johnston S, Brufsky A, Tilley WD, Overmoyer B. Palmieri C, et al. Among authors: schwartzberg ls. Lancet Oncol. 2024 Mar;25(3):317-325. doi: 10.1016/S1470-2045(24)00004-4. Epub 2024 Feb 8. Lancet Oncol. 2024. PMID: 38342115 Free article. Clinical Trial.

5

Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.

Anderson JN, Paladino AJ, Blue R, Dangerfield DT 2nd, Eggly S, Martin MY, Schwartzberg LS, Vidal GA, Graetz I. Anderson JN, et al. Among authors: schwartzberg ls. J Cancer Surviv. 2023 Dec 19. doi: 10.1007/s11764-023-01511-0. Online ahead of print. J Cancer Surviv. 2023. PMID: 38114711

6

An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer.

Paladino AJ, Pebley K, Kocak M, Krukowski RA, Waters TM, Vidal G, Schwartzberg LS, Curry AN, Graetz I. Paladino AJ, et al. Among authors: schwartzberg ls. BMC Health Serv Res. 2022 Nov 23;22(1):1403. doi: 10.1186/s12913-022-08705-9. BMC Health Serv Res. 2022. PMID: 36419005 Free PMC article.

7

Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial.

Graetz I, Hu X, Curry AN, Robles A, Vidal GA, Schwartzberg LS. Graetz I, et al. Among authors: schwartzberg ls. Cancer Med. 2023 Mar;12(5):6190-6199. doi: 10.1002/cam4.5351. Epub 2022 Oct 18. Cancer Med. 2023. PMID: 36258654 Free PMC article. Clinical Trial.

8

Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive Breast Cancer.

Hu X, Kaplan CM, Martin MY, Walker MS, Stepanski E, Schwartzberg LS, Vidal GA, Graetz I. Hu X, et al. Among authors: schwartzberg ls. Cancer Epidemiol Biomarkers Prev. 2023 Feb 6;32(2):167-174. doi: 10.1158/1055-9965.EPI-22-0692. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 36166516 Free PMC article.

9

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.

Schwartzberg LS, Li G, Tolba K, Bourla AB, Schulze K, Gadgil R, Fine A, Lofgren KT, Graf RP, Oxnard GR, Daniel D. Schwartzberg LS, et al. JTO Clin Res Rep. 2022 Aug 2;3(9):100386. doi: 10.1016/j.jtocrr.2022.100386. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36089920 Free PMC article.

10

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.

Hu X, Walker MS, Stepanski E, Kaplan CM, Martin MY, Vidal GA, Schwartzberg LS, Graetz I. Hu X, et al. Among authors: schwartzberg ls. JAMA Netw Open. 2022 Aug 1;5(8):e2225485. doi: 10.1001/jamanetworkopen.2022.25485. JAMA Netw Open. 2022. PMID: 35947386 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page